The present invention discloses a nutritional composition and method of using and making the nutritional composition. The nutritional composition is an intact pea protein based nutrient composition for use in both enteral and oral feeding, and provides a nonallergenic diet for providing optimal nutrition to users. The nutritional composition is made from organic and plant-based ingredients. The nutritional composition has pea protein, phytochemical extracts, fatty acids, organic ingredients free of the top eight allergens and corn, and prebiotic fiber. The nutritional composition is provided in liquid form for enteral and/or oral feeding.

The present invention discloses a nutritional composition and method of using and making the nutritional composition. The nutritional composition is an intact pea protein based nutrient composition for use in both enteral and oral feeding, and provides a nonallergenic diet for providing optimal nutrition to users. The nutritional composition is made from organic and plant-based ingredients. The nutritional composition has pea protein, phytochemical extracts, fatty acids, organic ingredients free of the top eight allergens and corn, and prebiotic fiber. The nutritional composition is provided in liquid form for enteral and/or oral feeding.

Disclosed herein are formulations, methods, and kits of formulations for inhibiting, ameliorating, delaying the onset of, reducing the likelihood of, treating, and/or preventing metabolic syndrome, and/or increasing energy levels. The formulations have at least one extract from a tart cherry, at least one antioxidant vitamin, at least one polyphenolic compound, and at least one prebiotic. Also disclosed are methods of making the formulations.

Disclosed herein are formulations, methods, and kits of formulations for inhibiting, ameliorating, delaying the onset of, reducing the likelihood of, treating, and/or preventing metabolic syndrome, and/or increasing energy levels. The formulations have at least one extract from a tart cherry, at least one antioxidant vitamin, at least one polyphenolic compound, and at least one prebiotic. Also disclosed are methods of making the formulations.

A particular Bifidobacterium spp. strain or particular Lactobacillus spp. strain according to the present invention is isolated from excrement of a human or cabbage kimchi, and thus is highly safe and has physiological activities such as an immunity regulatory effect and an inflammation reaction inhibiting effect. Therefore, the particular Bifidobacterium spp. strain or particular Lactobacillus spp. strain according to the present invention may be used as a material for regulating immunity and inhibiting inflammation reactions, and may be also used as a functional food and drug material useful for preventing, alleviating or treating rhinitis, atopy, asthma, etc. which are allergic diseases.

A particular Bifidobacterium spp. strain or particular Lactobacillus spp. strain according to the present invention is isolated from excrement of a human or cabbage kimchi, and thus is highly safe and has physiological activities such as an immunity regulatory effect and an inflammation reaction inhibiting effect. Therefore, the particular Bifidobacterium spp. strain or particular Lactobacillus spp. strain according to the present invention may be used as a material for regulating immunity and inhibiting inflammation reactions, and may be also used as a functional food and drug material useful for preventing, alleviating or treating rhinitis, atopy, asthma, etc. which are allergic diseases.

A vegetable product obtained from vegetable matter selected from at least one of root, tubers and leaves of a plant having inulin as a reserve carbohydrate, wherein the product includes particles having particle sizes in the range of 0.5 to 10 mm and including inulin and cell walls having pectin, hemi-cellulose and cellulose, wherein the inulin is contained within the cell walls, and the product is obtained by a process including the steps of: a) wounding the vegetable matter, b) treating the vegetable matter with an aqueous solution having an antioxidant and/or a textural support agent and heating the vegetable matter to a temperature of 40 to 90° C. and c) mechanically reducing the size of the vegetable matter and drying the vegetable matter to obtain the product.

A vegetable product obtained from vegetable matter selected from at least one of root, tubers and leaves of a plant having inulin as a reserve carbohydrate, wherein the product includes particles having particle sizes in the range of 0.5 to 10 mm and including inulin and cell walls having pectin, hemi-cellulose and cellulose, wherein the inulin is contained within the cell walls, and the product is obtained by a process including the steps of: a) wounding the vegetable matter, b) treating the vegetable matter with an aqueous solution having an antioxidant and/or a textural support agent and heating the vegetable matter to a temperature of 40 to 90° C. and c) mechanically reducing the size of the vegetable matter and drying the vegetable matter to obtain the product.

Provided is a prebiotic composition, including a kiwifruit fermented product, inulin, and fructooligosaccharide, where the weight ratio of the kiwifruit fermented product, the inulin, and the fructooligosaccharide is 3-4:2.5-4:2.5-4. Based on this, the prebiotic composition prepared from the kiwifruit fermented product and sugars can be used for improving an intestinal tract of a subject.

The present invention encompasses compositions and methods useful to treat or prevent Clostridium difficile antibiotic-associated colitis through administration of IL-25 and/or downstream cytokines IL-13, IL-4, and IL-5. It is disclosed herein that IL-25 expression is decreased during antibiotic treatment and during bacterial infection and that treatment with IL-25 protein is protective during infection. It is further disclosed herein the unexpected result that IL-25 treatment protects against C. difficile-associated mortality and morbidity. The present application further describes an unexpected result regarding eosinophils and their role in combating infection and their relationship to the effectiveness of IL-25.